Clinical Trial Update: A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR) [Phase 3]

View source ↗

Summary

This Phase 3 trial compared monthly versus as-needed ranibizumab in patients with subfoveal neovascular age-related macular degeneration, reporting visual outco…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Age-related Macular Degeneration | Phase 3 | Status: COMPLETED | Results posted: 2013-01-18